Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

45.76USD
24 Oct 2014
Price Change (% chg)

$0.04 (+0.09%)
Prev Close
$45.72
Open
$45.68
Day's High
$45.79
Day's Low
$44.92
Volume
191,692
Avg. Vol
187,039
52-wk High
$49.10
52-wk Low
$33.05

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.97
Market Cap (Mil.): $95,855.98
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.81

Financials

  NVO.N Industry Sector
P/E (TTM): 27.56 33.21 34.06
EPS (TTM): 1.66 -- --
ROI: 65.79 18.18 17.45
ROE: 71.98 18.85 18.26
Search Stocks

Novo Nordisk receives U.S. subpoena related to Danish factory

COPENHAGEN - Denmark's Novo Nordisk, the world's biggest maker of insulin, has received a U.S. subpoena requesting documents relating to potential manufacturing issues at its Kalundborg plant in Denmark, the company said on Friday.

24 Oct 2014

UPDATE 1-Novo Nordisk receives U.S. subpoena related to Danish factory

COPENHAGEN, Oct 24 - Denmark's Novo Nordisk , the world's biggest maker of insulin, has received a U.S. subpoena requesting documents relating to potential manufacturing issues at its Kalundborg plant in Denmark, the company said on Friday.

24 Oct 2014

Novo Nordisk gets U.S. subpoena related to Danish factory

Oct 24 - Denmark's Novo Nordisk, the world's biggest maker of insulin, said on Friday it had received a U.S. subpoena requesting documents regarding potential manufacturing issues at its giant Kalundborg facility in Denmark.

24 Oct 2014

Analysts see U.S. approval of Novo Nordisk's obesity drug by year-end

COPENHAGEN - The U.S. Food and Drug Administration is likely to approve Novo Nordisk's new drug to treat obesity this year, analysts said after wide expectations of an FDA decision late on Monday were not met.

21 Oct 2014

Novo Nordisk's NNIT to announce IPO next week - Berlingske daily

COPENHAGEN, Oct 15 - NNIT, the information technology unit of Danish pharmaceutical company Novo Nordisk , is expected to announce plans for an initial public offering (IPO) on the Nasdaq Copenhagen exchange next week, daily Berlingske reported on Wednesday.

15 Oct 2014

Novo Nordisk's next big idea: a once-weekly insulin shot

COPENHAGEN - Denmark's Novo Nordisk, the world's largest insulin maker, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world's first once-weekly insulin injection.

01 Oct 2014

NORDIC STOCKS - Factors to watch on Sept 19

HELSINKI, Sept 19 - The following stocks may be affected by newspaper reports and other factors on Friday:

19 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment: study

COPENHAGEN - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment -study

COPENHAGEN, Sept 18 - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

NORDIC STOCKS-Factors to watch on Sept 17

COPENHAGEN, Sept 17 - The following stocks may be affected by newspaper reports and other factors on Wednesday:

17 Sep 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €84.60 -0.30
Eli Lilly and Co (LLY.N) $66.06 +1.71

Earnings vs. Estimates

Search Stocks